These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38157540)

  • 1. MRI characteristics of H3 G34-mutant diffuse hemispheric gliomas and possible differentiation from IDH-wild-type glioblastomas in adolescents and young adults.
    Shao H; Gong J; Su X; Chen N; Li S; Yang X; Zhang S; Huang Z; Hu W; Gong Q; Liu Y; Yue Q
    J Neurosurg Pediatr; 2024 Mar; 33(3):236-244. PubMed ID: 38157540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: A case series and systematic review.
    Kurokawa R; Baba A; Kurokawa M; Pinarbasi ES; Makise N; Ota Y; Kim J; Srinivasan A; Moritani T
    J Neuroimaging; 2022 Jan; 32(1):17-27. PubMed ID: 34632671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.
    Picart T; Barritault M; Poncet D; Berner LP; Izquierdo C; Tabouret E; Figarella-Branger D; Idbaïh A; Bielle F; Bourg V; Vandenbos FB; Moyal EC; Uro-Coste E; Guyotat J; Honnorat J; Gabut M; Meyronet D; Ducray F
    Neurooncol Adv; 2021; 3(1):vdab061. PubMed ID: 34056608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
    Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L
    Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3 G34-mutant high-grade glioma.
    Lim KY; Won JK; Park CK; Kim SK; Choi SH; Kim T; Yun H; Park SH
    Brain Tumor Pathol; 2021 Jan; 38(1):4-13. PubMed ID: 32995948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?
    Hu W; Duan H; Zhong S; Zeng J; Mou Y
    J Transl Med; 2022 Feb; 20(1):64. PubMed ID: 35109850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of arterial spin labeling for objective assessment of intratumoral microvessels in diffuse hemispheric glioma, H3 G34R-mutant: A case report and literature review.
    Kitakami K; Beppu T; Sato Y; Kurose A; Ogasawara K
    Radiol Case Rep; 2023 Mar; 18(3):856-861. PubMed ID: 36589502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas.
    Setyawan NH; Choridah L; Nugroho HA; Malueka RG; Dwianingsih EK
    Cancer Imaging; 2024 Jan; 24(1):3. PubMed ID: 38167551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review.
    Kegoya Y; Otani Y; Inoue Y; Mizuta R; Higaki F; Washio K; Koizumi S; Kurozumi K; Ishida J; Fujii K; Yamamoto N; Tanaka Y; Date I
    J Neurooncol; 2024 Mar; 167(1):201-210. PubMed ID: 38427132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI Features May Predict Molecular Features of Glioblastoma in
    Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
    AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.
    Sim Y; Choi SH; Lee N; Park YW; Ahn SS; Chang JH; Kim SH; Lee SK
    Eur J Radiol; 2024 Apr; 173():111384. PubMed ID: 38422610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amide proton transfer-weighted imaging and derived radiomics in the classification of adult-type diffuse gliomas.
    Wu M; Jiang T; Guo M; Duan Y; Zhuo Z; Weng J; Xie C; Sun J; Li J; Cheng D; Liu X; Du J; Zhang X; Zhang Y; Liu Y
    Eur Radiol; 2024 May; 34(5):2986-2996. PubMed ID: 37855851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.